CRD1400

CRD1400 is a potent, small molecule inhibitor of acetyl-CoA synthetase short-chain family member 2 (ACSS2) developed by Curadev Pharma. It targets the metabolic pathway where acetate is converted into acetyl-CoA, a critical process for tumor cell survival and lipid synthesis, especially in hypoxic and nutrient-depleted microenvironments. By blocking ACSS2, CRD1400 disrupts the energy supply and building blocks for acetate-dependent tumors, such as gliomas and triple-negative breast cancer, and reduces lipid accumulation in metabolic conditions like hepatic steatosis. It has shown the ability to sensitize cancer cells to chemotherapy and is currently in preclinical development.

Other names

ACSS2 inhibitorACSS-2 inhibitorACSS 2 inhibitor